Related Experiment Video
Updated: Jun 23, 2026
07:53
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Biological reactive intermediates that mediate dacarbazine cytotoxicity
Jalal Pourahmad1, Marzieh Amirmostofian, Farzad Kobarfard
1Faculty of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, PO Box 14155-6153, Iran. j.pourahmadjaktaji@utoronto.ca
Cancer Chemotherapy and Pharmacology
|April 29, 2009
Summary
Dacarbazine causes liver cell damage by generating reactive oxygen species (ROS) and damaging lysosomes. Antioxidants and cytochrome P450 inhibitors protect against this dacarbazine-induced hepatotoxicity.
Area of Science:
- Hepatology
- Toxicology
- Biochemistry
Background:
- Dacarbazine is a chemotherapy drug.
- Understanding its mechanism of liver cell toxicity is crucial for patient safety.
Purpose of the Study:
- To investigate the cellular and molecular mechanisms of dacarbazine-induced cytotoxicity in isolated rat hepatocytes.
Main Methods:
- Utilized the Accelerated Cytotoxicity Screening (ACMS) technique.
- Investigated the role of reactive oxygen species (ROS), lysosomal integrity, and cytochrome P450 enzymes.
Main Results:
- Dacarbazine induced ROS formation and lysosomal membrane leakiness preceding hepatocyte lysis.
- ROS generation was linked to iron and inhibited by chelators and antioxidants.
- Cytochrome P450 inhibitors also prevented dacarbazine cytotoxicity.
- Dacarbazine triggered protease activation and proteolysis within hepatocytes.
Conclusions:
- Dacarbazine cytotoxicity is mediated by ROS (H2O2, O2*-) generation.
- H2O2 may react with lysosomal iron, causing membrane damage and enzyme release, leading to cell death.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...